News | Lung Imaging | October 28, 2015

Findings encourage practice change for lung cancer management

non-small cell lung cancer, NSCLC, IMRT, toxicity, intensity modulated radiation therapy, 3-D CRT, ASTRO 2015

October 28, 2015 — An analysis of an international, cooperative-led trial of patients with locally advanced non-small cell lung cancer (NSCLC) has shown that those who received intensity modulated radiation therapy (IMRT) had less severe lung toxicity. Those patients were also able to better tolerate their chemotherapy, compared to patients who received three-dimensional conformal radiation therapy (3-D CRT).

Stephen Chun, M.D., fellow, radiation oncology at The University of Texas MD Anderson Cancer Center, presented the research at the American Society for Radiation Oncology’s (ASTRO) 57th Annual Meeting.

According to the American Cancer Society, in the United States, 221,200 will be diagnosed with lung cancer in 2015 and 158,040 will die from the disease. About a third of all lung cancers are diagnosed when the cancer is locally advanced, said Chun. The standard of care for locally advanced lung cancer is concurrent chemotherapy and radiation, with most patients receiving either 3-D CRT or IMRT.

For decades, 3-D CRT has been the standard of care for the treatment of lung cancer. The technique shapes radiation beams aimed in straight lines to match the shape of the tumor. In contrast, IMRT is a newer, more-advanced technique that sculpts and molds radiation beams to tumor targets, using substantially more complex radiation beam arrangements than 3D-CRT. In turn, IMRT can spare more normal tissue than 3D-CRT with high doses of radiation, explained Chun.

“IMRT was developed more than a decade ago and because it’s been shown to reduce toxicity, it has been accepted to treat prostate, brain, and head & neck cancers,” said Chun, the study’s lead author. “There have been a number of smaller studies, including research led by MD Anderson, looking at IMRT and lung cancer. This is the first analysis of a prospective clinical trial to show a reduction of toxicity associated with IMRT in locally advanced lung cancer and could lead to a major change in the way radiation therapy is delivered for the disease.

“The data from our study makes a strong argument that we should routinely consider use of IMRT in locally advanced lung cancer,” Chun continued.

This study is a secondary analysis of data collected from the NRG/RTOG 0617, a large, multi-center phase III randomized trial of patients with locally advanced NSCLC. The study originally enrolled patients from 2007 to 2011 and compared a high dose of 74 Gy to the standard dose of 60 Gy. All underwent concurrent chemotherapy (carboplatin/paclitaxel, with or without cetuximab) and either 3-D CRT or IMRT. In NRG/RTOG 0617, 482 patients were treated with radiation – 53 percent with IMRT and 47 percent with 3-D CRT.

The study found 44 percent fewer cases of severe pneumonitis (defined by the researchers as lung inflammation that required oxygen, steroids or mechanical ventilation, and/or led to death) in patients who received IMRT – 3.5 percent of patients, despite having larger tumors, compared to 7.9 percent of the 3-D CRT group. While the benefit of IMRT was seen in all tumor sizes, the reduction of severe pneumonitis was more pronounced in larger tumors, explained Chun.

Additionally, those who received IMRT were more likely to complete consolidative chemotherapy – 37 percent, compared to 29 percent in those treated with 3D-CRT. High-dose chemotherapy after completing chemotherapy with radiation is considered to be standard for locally advanced lung cancer.

One of the principles of IMRT, explained Chun, is to bring in many complex beams to converge on a target, producing a high dose on the target and dramatically sparing nearby adjacent tissue. By using multiple beam arrangements, this leads to spreading of a low-dose bath such as the volume of lung that received 5 Gy of radiation.

“It’s been unclear what the consequences of that low-dose bath are. What we’ve seen in this study is that indicators of the low-dose bath that’s increased by IMRT had no association with any severe toxicity outcome. This finding suggests that we should be optimizing radiation treatment by the high and intermediate dose region, and not the low-dose region,” said Chun.

IMRT is more time-intensive and costly, said Chun, yet the study showed a dramatic reduction in severe toxicities. These findings have the potential to reduce the number of hospital admissions and improve quality of life for this patient population, he explained.

For more information: www.astro.org

Related Content

Videos | Radiation Therapy

Jeffrey T. Chapman, a medical student at the University of Texas Southwestern Medical Center, Explains how watching ...

Time November 24, 2021
arrow
News | Lung Imaging

November 23, 2021 — Median Technologies announces new outstanding performance of its lung cancer screening (LCS) CADx1 ...

Time November 23, 2021
arrow
News | Artificial Intelligence

November 22, 2021 — Sirona Medical, a software company founded on a deep understanding of both the practice and business ...

Time November 22, 2021
arrow
News | Coronavirus (COVID-19)

November 22, 2021 — Lung autopsy and plasma samples from people who died of COVID-19 have provided a clearer picture of ...

Time November 22, 2021
arrow
News | Lung Imaging

November 19, 2021 — Lung cancer screening is recommended only for those who are at high risk for the disease — adults ...

Time November 19, 2021
arrow
News | X-Ray

November 19, 2021 — “Data drive decisions and with the latest trial data, we are positioned for growth,” said Amol ...

Time November 19, 2021
arrow
News | Artificial Intelligence

November 18, 2021 — Worldwide the most common cause of cancer mortality in 2020 was lung cancer, with an estimated 1.80 ...

Time November 18, 2021
arrow
News | Artificial Intelligence

November 18, 2021 — VIDA Diagnostics Inc. (VIDA) is further removing friction in respiratory clinical trials with the ...

Time November 18, 2021
arrow
Videos | Radiopharmaceuticals and Tracers

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins ...

Time November 17, 2021
arrow
Videos | Radiation Therapy

The Elekta Harmony radiotherapy system gained FDA clearance in the summer of 2021 and was on display for the first time ...

Time November 17, 2021
arrow
Subscribe Now